NCT04381091No Longer Available不适用
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study
详细描述
see above
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who completed the LEROS study, who attended the end of study visit in LEROS and who in the opinion of investigator could benefit from continuation of idebenone treatment.
- •Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the patient).
排除标准
- •Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability of idebenone treatment in LEROS trial.
- •Patients who prematurely discontinued the LEROS study.
研究者
相似试验
No Longer Available
不适用
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT03433807Santhera Pharmaceuticals
终止
3 期
Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)Duchenne Muscular DystrophyNCT03603288Santhera Pharmaceuticals161
Approved For Marketing
不适用
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilThyroid CancerNCT03533361Eisai Inc.
No Longer Available
不适用
Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic SyndromesMyelodysplastic SyndromesNCT04484363Takeda
Available
不适用
Individual Patient Compassionate Use of FedratinibMyelofibrosisNCT03723148Celgene